These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34896029)

  • 1. Temporal trends of pharmacologic treatments for tuberculosis and multidrug resistant tuberculosis following dissemination of treatment guidelines in South Korea.
    Jeong HE; Choi J; Oh IS; Son H; Jang SH; Jung SY; Shin JY
    J Microbiol Immunol Infect; 2022 Oct; 55(5):917-925. PubMed ID: 34896029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
    Mok JH; Kang BH; Lee T; Lee HK; Jang HJ; Cho YJ; Jeon D
    J Korean Med Sci; 2017 Apr; 32(4):636-641. PubMed ID: 28244290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additional Drug Resistance in Patients with Multidrug-resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019.
    Lee T; Lee SJ; Jeon D; Lee HY; Kim HJ; Kang BH; Mok J
    J Korean Med Sci; 2021 Jul; 36(26):e174. PubMed ID: 34227261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular Activity of Poly (DL-Lactide-co-Glycolide) Nanoparticles Encapsulated with Prothionamide, Pyrazinamide, Levofloxacin, Linezolid, or Ethambutol on Multidrug-Resistant
    Jiang H; Li X; Xing Z; Niu Q; Xu J
    Curr Drug Deliv; 2023; 20(3):306-316. PubMed ID: 35546770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee
    J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia.
    Mesfin EA; Beyene D; Tesfaye A; Admasu A; Addise D; Amare M; Dagne B; Yaregal Z; Tesfaye E; Tessema B
    PLoS One; 2018; 13(6):e0197737. PubMed ID: 29864118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China.
    Xia H; van den Hof S; Cobelens F; Zhou Y; Zhao B; Wang S; Zhao Y
    BMC Infect Dis; 2020 Jan; 20(1):19. PubMed ID: 31910878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK; Kim JH; Kang H; Cho JS; Smego RA
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
    Park S; Jo KW; Lee SD; Kim WS; Shim TS
    Respir Med; 2017 Oct; 131():43-48. PubMed ID: 28947041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-administered, standardized regimens for multidrug-resistant tuberculosis in South Korea.
    Park SK; Lee WC; Lee DH; Mitnick CD; Han L; Seung KJ
    Int J Tuberc Lung Dis; 2004 Mar; 8(3):361-8. PubMed ID: 15139476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
    Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial.
    Weng T; Sun F; Li Y; Chen J; Chen X; Li R; Ge S; Zhao Y; Zhang W
    BMC Infect Dis; 2021 Feb; 21(1):183. PubMed ID: 33596848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-2017.
    Glasauer S; Altmann D; Hauer B; Brodhun B; Haas W; Perumal N
    PLoS One; 2019; 14(6):e0217597. PubMed ID: 31188848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevalence and transmission of pyrazinamide-resistant
    Liu BB; Hu PL; Chen ZH; Yi SL; Zhang XP; Tan YH
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Jul; 45(7):677-685. PubMed ID: 35768376
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevalence of Multi-Drug Resistant
    Ali S; Khan MT; Khan AS; Mohammad N; Khan MM; Ahmad S; Noor S; Jabbar A; Daire C; Hassan F
    Pol J Microbiol; 2020; 69(2):1-5. PubMed ID: 32249555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pyrazinamide Susceptibility and
    Rahman A; Ferdous SS; Ahmed S; Rahman SMM; Uddin MKM; Pholwat S; Gratz J; Houpt E; Banu S
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Screening Versus Phenotypic Susceptibility Testing of Multidrug-Resistant Mycobacterium tuberculosis Isolates for Streptomycin and Ethambutol.
    Al-Mutairi NM; Ahmad S; Mokaddas E
    Microb Drug Resist; 2018 Sep; 24(7):923-931. PubMed ID: 29336677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China.
    Che Y; Bo D; Lin X; Chen T; He T; Lin Y
    BMC Infect Dis; 2021 Jun; 21(1):605. PubMed ID: 34171989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistant tuberculosis in Saudi Arabia: an analysis of surveillance data 2014-2015.
    Al Ammari M; Al Turaiki A; Al Essa M; Kashkary AM; Eltigani SA; Ahmed AE
    Antimicrob Resist Infect Control; 2018; 7():12. PubMed ID: 29387346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.